The Effects Of Ganglioside And Nerve Growth Factor On The Patients Of Acute Craniocerebral Injured Serum Nuron Specific Enolase And S100B Protein Concentration

Obiectives:This study combined detection of serum NSE and S100B protein concentration dynamic changes in patients of acute craniocerebral injured, to observe the serum NSE and S100B protein affect concentration of the ganglioside and/or nerve growth factor, to explore ganglioside and/or nerve growth factor to brain protective effect and the treatment of acute traumatic brain injury patients.Methods:Select20healthy subjects, the measurement of serum NSE and S100protein concentration, as a healthy control E group. The121patients (GCS score6-8points) with acute brain injury that meet the selection criteria for the treatment group were randomly divided into group A (without ganglioside and nerve growth factor), group B (simple use of ganglioside treatment), group C (simple to use nerve growth factor treatment), D group (associated with ganglioside and nerve growth factor treatment). Respectively fasting peripheral venous blood collection by traumatic brain injury patients, in6hours,24hours,48hours,72hours and120hours after admission, to detect patients with serum NSE and S100changes in protein concentration after separation of serum by enzyme-linked immunosorbent assay, and statistical comparative analysis.Results:It was significantly higher that A, B, C, D groups of patients with acute craniocerebral injured that NSE and S100B protein concentration than E in the6,24,48,72,120hours after admission, there are statistically significant (p<0.01), and reached the peak in the24hours after admission, decreasing with time;It was significantly lower that B, C, D groups of patients with acute craniocerebral injured that NSE and S100B protein concentration than E that drug therapy has not been neurotrophic at each time point, the difference was statistically significant (p<0.05); It was no significant difference that the serum NSE and S100B protein concentrations of groups B compared with C groups of patients, the difference was not statistically significant (p>0.05);the serum NSE and S100B protein concentration of the group D patients combination therapy by using gangliosides and nerve growth factor, are reduced compared with B, C groups at each time point, there is statistically significant (p<0.05).Conclusions:1. Ganglioside and nerve growth factor were able to reduce the serum of NSE and S100B protein concentration of patients with acute craniocerebral injury, have a protective role in the brain, and it was no significant difference that the therapeutic effect of the two drugs.2. Joint use of ganglioside and nerve growth factor treatment of acute brain injury patients, serum NSE and S100B protein concentration more pronounced decline than the ganglioside alone or nerve growth factor in patients, two drugs have synergistic brain protection.2figures,2tables,61references.